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Multifunctional Clickable Reagents for Rapid Bioorthogonal
Astatination and Radio-Crosslinking
Christoph Denk,[a] Martin Wilkovitsch,[a] Emma Aneheim,[b] Matthias M. Herth,[c, d]
Holger Jensen,[d] Sture Lindegren,[b] and Hannes Mikula*[a]
In the past decade, several developments have expanded the
chemical toolbox for astatination and the preparation of 211At-
labeled radiopharmaceuticals. However, there is still a need for
advanced methods for the synthesis of astatinated (bio)
molecules to address challenges such as limited in vivo stability.
Herein, we report the development of multifunctional 211At-
labeled reagents that can be prepared by applying a modular
and versatile click approach for rapid assembly. The introduc-
tion of tetrazines as bioorthogonal tags enables rapid radio-
labeling and radio-crosslinking, which is demonstrated by steric
shielding of 211At to significantly increase label stability in
human blood plasma.
Astatine-211 is considered as one of the most promising α-
particle emitting radionuclides for therapeutic application.[1–3] Its
favorable physical properties include (i) a half-life time of 7.2 h
compatible with the pharmacokinetics of potential targeting
carriers, (ii) an α-particle emission yield of 100%, (iii) no long-
lived α-emitting decay products, and (iv) a high linear energy
deposition enabling effective cell-killing.[4–8] These features
motivated the development and evaluation of therapeutic
strategies applying a variety of 211At-labeled radio-pharmaceut-
icals such as monoclonal antibodies,[6,8–10] antibody fragments,[11]
nanobodies,[12] diabodies,[13] and other carriers.[14–15] Despite the
potential of 211At for medical use, its application has been
impeded mainly by the low in vivo stability of labeled
compounds.[1–2] Several labeling strategies and reagents have
been developed including (i) conjugation with astatobenzoates,
or (ii) radiohalogenation of boron cage moieties,[1,4,7,16–21] or (iii)
copper-catalyzed astatination of boronic esters.[22] However,
additional studies and methodologies are required to enable
further advancement in the field of 211At-based radiotherapy. In
this regard, researchers are facing several challenges related to
astatine, which is not only one of the rarest naturally occurring
elements, but also has no stable isotope. Consequently, the
chemistry of astatine is yet not fully understood and many
properties have only been extrapolated.[2]
Astatine-211 is produced by irradiation of stable bismuth
with 28MeV α-particles in the 209Bi(α,2n)211At reaction followed
by isolation from the target material and used for subsequent
labeling.[23] As there is no existing stable isotope, non-radio-
active astatine-labeled compounds cannot be prepared and
used as reference material, e.g. to enable identification of 211At-
labeled compounds by HPLC after radiosynthesis. Therefore,
iodine-labeled analogs are often used as reference compounds,
not only for analytics, but also to study in vivo deastatination by
comparison with structurally equivalent 211At-labeled com-
pounds, although significant differences of 211At and iodine
have been reported.[1,16] Another drawback of 211At-radiophar-
maceuticals is that several manual steps are often required in
the production process.[23] Thus, further advancements rely on
the development of efficient and rapid methods for the
synthesis of astatinated (bio)molecules.
In order to circumvent problems related to astatine
chemistry and to simplify and accelerate the preparation of
211At-labeled compounds, we aimed to develop multifunctional
reagents that can be used for radiolabeling and radio-cross-
linking applying bioorthogonal chemistry, also focusing on the
potential effect of steric shielding (Figure 1).
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Figure 1. Rapid assembly of multifunctional 211At-reagents applicable for
rapid bioorthogonal radiolabeling, crosslinking and/or steric shielding to
increase label stability.
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The development of rapid, modular and highly selective
bioorthogonal ligations has led to numerous applications of
click reactions in radiochemistry. In particular, tetrazine ligations
– the fastest bioorthogonal reactions described so far[24] – have
had a significant impact by enabling strategies for (i) rapid
radiolabeling using prosthetic groups, (ii) site-specific radio-
labeling, and (iii) pretargeting approaches based on in vivo
chemistry.[25–27] To this end, various radiolabeled 1,2,4,5-tetra-
zines (Tz) have been developed as clickable tools for PET and
SPECT imaging (18F, 11C, 111In, 64Cu, 123I, 125I),[28–33] and targeted
radiotherapy (177Lu, 67Cu)[34,35] making use of the fast bioorthog-
onal ligation with trans-cyclooctenes (TCO).
Recently, the first Tz labeled with α-emitting radionuclides
(i. e. 212Pb and 225Ac) have been reported aiming at the
advantages of α-emitters over β  -emitting radionuclides such
as the delivery of a higher radiation dose within a shorter path
length.[36,37]
Considering the potential and capability of both, 211At-based
radiotherapy and bioorthogonal chemistry, we focused on the
synthesis of 211At-labeled clickable reagents inspired by the
pioneering study of Årstad and coworkers describing a modular
three-component reaction for the synthesis of 125I-labeled
compounds.[38] Based on this approach we have been successful
to access 211At-labeled compounds by copper-catalyzed click-
assembly of terminal alkynes, azido-functionalized molecules and
astatine-211 (2.4-2.6 MBq) (Figure 2a). This method was further
investigated and optimized with emphasis on reaction temper-
ature and time to reach radiochemical yields >70% in 10 min
(Figure 2b). Using this procedure, we were able to prepare a
variety of 211At-labeled compounds (1-12, Figure 2c) showing
compatibility with different functional groups including moieties
such as biotin (4, 8, 12) and tetrazines (5–12). Even more reactive
and thus less stable mono-substituted tetrazines (H-tetrazines,
H  Tz) were used for the synthesis of bioorthogonal 211At-labeled
agents (9–12) in radiochemical yields of >50% (except compound
11) similar to more stable methyl-tetrazines (5–8) (Figure 2d).
To test for compatibility with higher activities, compound 1
was prepared using 33 MBq of astatine-211 in a radiochemical
yield of 87% (see Supplementary Information). Moreover, high
radiochemical purities were achieved in most cases already prior
to further purification and impurities could readily be removed by
preparative radio-HPLC (see Supporting Information).
To verify correct click-assembly as shown in Figure 1a and
bioorthogonal reactivity, we used the multifunctional biotinylated
211At-tetrazine 12 in a scavenging experiment exploiting the
orthogonal reactivity of both functional moieties (Tz/TCO vs.
biotin/streptavidin). Magnetic beads functionalized with either
TCO or streptavidin were used to remove 12 from solution
through rapid ligation to the beads followed by magnetic
separation (Figure 3). Compound 3 was used in control experi-
ments to test and correct for unspecific binding to the beads (as
partly observed with TCO-beads). In this experiment we could
Figure 2. (a) Rapid and modular assembly of 211At-labeled compounds applying a three-component copper-catalyzed click reaction. (b) The radiochemical
yield of click-astatination depends on reaction time and temperature as shown for the synthesis of 1. (c) Synthesized 211At-labeled compounds 1–12 including
methyl-substituted tetrazines, more reactive H-tetrazines and the two multifunctional biotinylated 211At-tetrazines 8 and 12. (d) Radiochemical yields of
compounds 1–12 (10 min reaction time, 60 °C, 2.4–2.6 MBq 211At) as determined by radio-HPLC (see Supporting Information; n=1).
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show efficient Tz-driven and biotin-driven removal of 12 with
remaining activities in solution of ~5% and ~7%, respectively, in
comparison to ~72% and ~98%, respectively, for control 3
(Figure 3c). Hence, both moieties, Tz and biotin, were detected,
strongly indicating successful three-component click-assembly. In
addition, 211At-labeled tetrazine 9 was compared to its iodine-
labeled analog by HPLC showing similar retention times for both
compounds (see Supporting Information).
Radio-crosslinking on beads was carried out following a similar
approach by reacting functionalized beads with 12 followed by
reaction with streptavidin or TCO-labeled poly(ethylene glycol)
with an average molecular weight of 2 kDa (PEG(2k)), respectively
(Figure 4a and Figure 4b). To investigate steric shielding of
conjugated 12 (and the attached 211At-label) by streptavidin or
TCO-PEG(2k) the radio-crosslinked beads were incubated in
human blood plasma at 37°C for 5 hours. Radioactivity was
measured in solution after magnetic separation of the beads
revealing significantly reduced degradation compared to un-
shielded controls (Figure 4c). In case of PEG(2k)-shielding we
observed a degradation (or deastatination) of less than 1% and
thus a more than 10-fold increased stability in human blood
plasma. Although these findings cannot directly be translated to
in vivo conditions, we consider steric shielding through radio-
crosslinking as a strategy to potentially further improve the
stability of 211At-labeled radiopharmaceuticals. Furthermore, multi-
functional clickable 211At-reagents such as 12 represent advanta-
geous and broadly applicable tools for radiolabeling and sub-
sequent surface modification of (nano)particles applying rapid
radio-crosslinking. As click chemistry has become a commonly
used method for engineering nanoparticle surfaces,[39,40] radio-
crosslinking could be applied to simultaneously incorporate 211At
during surface modification to rapidly access nano-radiopharma-
ceuticals for theranostic applications[41–43] without the need for
additional labeling procedures.
In summary, we have developed an efficient method for
rapid assembly of astatinated compounds tolerating highly
Figure 3. (a) Structure Verification of 211At-labeled compounds using multifunctional compound 12, non-reactive compound 3 as a control, and functionalized
magnetic beads. (b) Compound 12 was reacted with either TCO- or streptavidin-functionalized beads and radioactivity was measured after magnetic
separation. (c) Both Tz-driven removal of 12 based on bioorthogonal ligation to TCO-beads and biotin-driven removal by binding to streptavidin-beads was
shown (in comparison to control experiments using compound 3 to correct for unspecific binding to the beads).
Figure 4. Radio-crosslinking using the biotinylated 211At-tetrazine 12. (a) TCO-beads were reacted with 12 by bioorthogonal Tz ligation followed by shielding
with streptavidin. (b) In an analogous experiment, streptavidin-functionalized beads were radio-crosslinked with 12 to TCO-PEG(2k). (c) Steric shielding of 12
(on beads) with either streptavidin or TCO-PEG(2k) was shown to significantly reduce degradation/deastatination and thus increase label stability (up to >10-
fold) in human blood plasma (incubation time of 5 hours) in comparison to unshielded 12 on beads as a control.
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reactive bioorthogonal functional groups such as 1,2,4,5-
tetrazines. We thus present the synthesis of the first 211At-
labeled clickable tools that can be used for rapid radiolabeling
applying tetrazine ligations. Moreover, multifunctional reagents
can easily be prepared and used for radio-crosslinking. This
approach was found to be a promising strategy for surface
modification and simultaneous incorporation of 211At. The
observed increased stability in human blood plasma through
steric shielding further illustrates the potential application of
this methodology. Hence, we are convinced that our results will
significantly contribute to further research in the field of 211At-
labeling and the development of new and improved radio-
pharmaceuticals.
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